Can you drink alcohol on low-dose naltrexone (LDN)?
Reviewed 16 sourcesPublished by PepVault
What the naltrexone labels say about alcohol, how far LDN blocks opioid receptors next to the 50 mg dose, and the two trials that gave LDN to heavy drinkers.

- Last reviewed
- Sources
- 16
- Questions
- 7
- Compounds
- 1
The short answer
No naltrexone label warns against drinking during treatment, and it causes no disulfiram-style sickness when you drink. LDN is 1 to 5 mg; the 50 mg tablet is the dose approved to help people drink less. No trial has tested LDN to cut drinking; in two small pain trials in people with past-year heavy drinking, it was well tolerated and did not lower drinking. How much is your prescriber's call.
Evidence: FDA labels and large randomized trials for 50 mg naltrexone in alcohol dependence; for LDN doses with alcohol, two small pain trials in heavy drinkers (8 and 15 people on LDN) and no trial of drinking as the goal.

What do the naltrexone labels say about alcohol?
Naltrexone is the rare medicine whose approved use is alcohol itself. The 50 mg tablet is "indicated in the treatment of alcohol dependence" and for blocking the effects of opioids1. The tablet label carries no warning against drinking, and the injection's asks only that you not be drinking at the first shot2. Both say the opposite of what people fear: naltrexone "is not aversive therapy and does not cause a disulfiram-like reaction either as a result of opiate use or ethanol ingestion"12. Disulfiram (Antabuse) makes a drink cause flushing and vomiting; naltrexone does not.
Low-dose naltrexone, or LDN, is the same molecule at about a tenth of that dose, prescribed off-label (for a use no label covers; see pepvault.app/glossary/off-label) and usually made by a compounding pharmacy. No LDN product has a label, so the 50 mg label and the monthly injection's label are the closest written rules.
| What it covers | Naltrexone tablet, 50 mg1 | Vivitrol injection, 380 mg monthly2 | LDN, 1 to 5 mg |
|---|---|---|---|
| Approved for | Alcohol dependence; blocking opioids | Alcohol dependence; preventing relapse to opioids | Nothing: off-label |
| Drinking while on it | No warning against it; no disulfiram-like reaction | Should not be drinking at the first injection; no disulfiram-like reaction | No label |
| Liver | Hepatitis and liver dysfunction reported; exposure 5 to 10 times higher in cirrhosis | Hepatitis reported; stop if signs of acute hepatitis appear | No label; a tenth or less of the tablet dose |
| Opioids | Not with opioid painkillers or opioid dependence; be opioid-free, tramadol included, before starting | Not with opioid painkillers or current opioid dependence | The same block applies |
Labels as read on November 20, 2026: naltrexone hydrochloride tablets USP 50 mg on DailyMed (version 10, published November 16, 2026) and Vivitrol on DailyMed (version 39, published July 24, 2026).
PepVault logs LDN as a daily oral dose with a reminder at the time you set, so every dose you take sits in your history. Set reminders in PepVault

How is LDN different from the 50 mg dose?
The difference is how many of the brain's mu-opioid receptors are blocked, and for how long. A receptor is a lock on a cell; naltrexone sits in the opioid lock without turning it. At 50 mg the block is near complete and lasts. In five volunteers scanned with a tracer that lights up free mu receptors, 50 mg gave blood levels "in excess of that needed to saturate" them, and the block took 72 to 108 hours to fall by half3. The label puts it in practice: 50 mg blocks an injected 25 mg dose of heroin for up to 24 hours1.
Low doses block far less. In healthy men given single doses of 2 to 50 mg, the dose that blocked half the mu receptors in the first 8 hours was 5.6 mg4. That puts the common LDN dose of 4.5 mg below half. The tablet's own half-life is about 4 hours, and its active breakdown product's about 13 (see pepvault.app/glossary/half-life)1.
| Dose | Share of mu receptors blocked in the first hours | Where the figure comes from |
|---|---|---|
| 1 to 3 mg | About 15 to 35% | Our calculation from the 5.6 mg midpoint4 |
| 4.5 mg (the usual LDN dose) | About 45% | Our calculation from the 5.6 mg midpoint4 |
| 5.6 mg | 50% | Measured midpoint4 |
| 50 mg (the approved dose) | Near complete, lasting days | Measured3; about 90% by the same calculation |
The middle column applies a standard one-site dose curve to the study's 5.6 mg midpoint; the study measured the midpoint, not each row. Block rose with time after a dose at the same blood level, so these are first-hours figures4.
Why does naltrexone change drinking at all?
Because part of a drink's reward runs through your own opioids. In a brain-scan study, drinking alcohol released endorphins, the body's own opioids, in the nucleus accumbens and the orbitofrontal cortex, two reward areas; in heavy drinkers, more release in the orbitofrontal cortex went with a bigger subjective high5. Naltrexone sits on the receptors those endorphins need.
Pooled laboratory studies show what that feels like: on naltrexone, alcohol gave less craving and less stimulation, more sedation and a lower mood, each a small effect6. In a crossover study of 19 social drinkers, 50 mg did not change how fast alcohol was absorbed or cleared and did not change performance on tasks, while it made the drink more sedating and less rewarding7. So naltrexone does not make alcohol more dangerous in the blood; it makes it less worth having. Whether a dose that blocks under half the receptors does the same has not been measured.
Has any trial tested LDN and alcohol?
No trial has tested LDN as a way to drink less, and a search of ClinicalTrials.gov on November 20, 2026 found none registered16. Two small trials gave 4.5 mg to people who had drunk heavily in the past year, to treat their pain, and recorded drinking along the way.
| Trial | Who | LDN dose and length | What happened with alcohol |
|---|---|---|---|
| Bendiks 20238 | People with HIV, chronic pain and heavy drinking in the past year, St. Petersburg | 4.5 mg, 8 weeks; 8 people on LDN | Well tolerated: median tolerability 100 of 100; 1 of 8 stopped. Drinking did not fall: about 5.5 g more alcohol a day at 8 weeks |
| Tsui 20249 | The same team and population; 45 people, 15 per arm, about 2 heavy drinking days a month at the start | 4.5 mg vs gabapentin vs placebo, 8 weeks | The share of heavy drinking days rose 3.1 points on LDN and fell 4.6 on placebo: no significant difference; pain no better than placebo |
| Roberts 2018, laboratory10 | 30 heavy-drinking smokers | 25 mg (half the approved dose) with varenicline | Given alcohol to a breath level of 0.030 g/dL in the lab; adding naltrexone did not improve smoking outcomes |
In the 2024 trial, the LDN arm logged 13 side effects against 5 on placebo, 9 of the 13 mild, and one person had a serious event that needed medical care9. The plain reading: at 4.5 mg, people who kept drinking tolerated LDN, and LDN did not reduce their drinking.
What does the 50 mg dose do to drinking?
It helps, modestly. In one of the label's 12-week trials, of 104 people, 51% stayed abstinent on 50 mg against 23% on placebo, and 31% relapsed against 60%1. A Cochrane review of 50 trials with 7,793 people found naltrexone cut the risk of heavy drinking to 83% of placebo's14. A 2023 review found that 11 people need to take 50 mg for one to avoid a return to heavy drinking15.
The search "naltrexone to stop drinking" often leads to the Sinclair method, also called targeted naltrexone: take the 50 mg tablet before drinking, not every day, and keep drinking while the drug blocks the reward, so the habit weakens. Its author based it on his animal studies in which opioid blockers worked when paired with drinking and not during abstinence11. In a Finnish trial of 121 people, 27% on naltrexone with coping-skills therapy had no relapse to heavy drinking over 32 weeks against 3% on placebo with the same therapy, the last 20 weeks taken only when craving12. In a US trial of 163 problem drinkers, men on targeted naltrexone drank less per day by week 1213.
The injection's label leans the other way: 380 mg cut heavy drinking days across its trial, but the fuller benefit, fewer drinking days and more people abstinent throughout, showed in the 8% who had stopped drinking the week before the first shot and was not evident in the 92% still drinking2. Every one of these trials used 50 mg or the injection; none used LDN. For how GLP-1 medicines compare on drinking, see pepvault.app/guides/glp-1-and-alcohol-cravings.
Does alcohol with naltrexone hurt the liver?
The liver is where both meet. The label reports hepatitis and liver dysfunction with naltrexone, and the clearest harm came in trials of up to 300 mg a day, where liver injury appeared in "a substantial proportion" of people1. When liver enzymes rose at usual doses, there were often other causes, alcoholic liver disease among them1. In cirrhosis, exposure to naltrexone runs about 5 times higher, and 10 times once cirrhosis is advanced1.
LDN sits at a tenth of the approved dose or less, and no liver study has tested it with alcohol. Liver health and how much you drink are the two facts your prescriber weighs most.
Commonly reported: people on LDN say a drink or two feels much the same as before; on the 50 mg dose many say alcohol feels flatter and they stop sooner, and some notice nausea after drinking.
PepVault keeps your bloodwork, ALT included, beside the dose log, and the doctor's report puts both on one page for your prescriber. Log it in PepVault
When to get help If you notice signs of liver trouble, such as yellowing of the skin or eyes, contact your prescriber: the label advises medical attention for symptoms of acute hepatitis1.
What should you tell your prescriber if you drink on LDN?
- Say how much you drink in a usual week, counted in standard drinks, and how often you have more on one day.
- Name every opioid you take or might take, tramadol and opioid cough and cold medicines included: the label rules naltrexone out with opioid painkillers and says opioid medicines may not work on it1. Before surgery or dental work, see pepvault.app/guides/ldn-before-surgery.
- Ask whether a liver blood test makes sense, given your drinking: the label warns of liver injury1.
- If you would like to drink less, say so: the approved dose for that is 50 mg, and switching is your prescriber's decision1.
- Note how you feel after drinking in the first weeks, so you bring a record, not a memory.
The daily check-in on PepVault's Today screen has a note field: write the day's drinks there, and each note is saved to its day beside your logged doses. Log it in PepVault
LDN's uses and every trial by condition are in pepvault.app/guides/low-dose-naltrexone and on its library page, pepvault.app/peptides/low-dose-naltrexone, with its side effects at pepvault.app/peptides/low-dose-naltrexone/side-effects. The same question for other medicines: pepvault.app/guides/metformin-and-alcohol and pepvault.app/guides/nac-and-alcohol.
Sources
- Naltrexone hydrochloride tablets USP 50 mg, prescribing information (RemedyRepack). DailyMed, version 10, published November 16, 2026: Indications and usage; Clinical pharmacology; Clinical trials; Warnings; Precautions; Dosage and administration. dailymed.nlm.nih.gov
- Vivitrol (naltrexone for extended-release injectable suspension), prescribing information (Alkermes). DailyMed, version 39, published July 24, 2026: sections 1.1, 5, 12.1 and 14. dailymed.nlm.nih.gov
- Lee MC et al. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1988. PubMed 2839637
- Rabiner EA et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011. PubMed 21502953
- Mitchell JM et al. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med. 2012. PubMed 22238334
- Ray LA et al. Naltrexone effects on subjective responses to alcohol in the human laboratory: a systematic review and meta-analysis. Addict Biol. 2019. PubMed 31148304
- Swift RM et al. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 1994. PubMed 8092339
- Bendiks S et al. Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial. AIDS Care. 2023. PubMed 33682527
- Tsui JI et al. Pilot RCT comparing low-dose naltrexone, gabapentin and placebo to reduce pain among people with HIV with alcohol problems. PLoS One. 2024. PubMed 38408060
- Roberts W et al. Effects of varenicline alone and in combination with low-dose naltrexone on alcohol-primed smoking in heavy-drinking tobacco users: a preliminary laboratory study. J Addict Med. 2018. PubMed 29438157
- Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001. PubMed 11139409
- Heinälä P et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001. PubMed 11386491
- Kranzler HR et al. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol. 2009. PubMed 19593174
- Rösner S et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010. PubMed 21154349
- McPheeters M et al. Pharmacotherapy for alcohol use disorder: a systematic review and meta-analysis. JAMA. 2023. PubMed 37934220
- ClinicalTrials.gov, search for the intervention "low dose naltrexone" and the condition "alcohol" (4 records: two LDN pain trials in heavy drinkers, a naltrexone implant trial and an N-acetylcysteine plus naltrexone trial), accessed November 20, 2026. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.